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j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrPreface to Hsp90The heat-shock protein 90 (Hsp90) is more than a single protein. It
is at the heart of a ubiquitous and conserved molecular machine with
a large cohort of more or less constant parts. Hsp90, already present
in prokaryotes, is essential and extremely abundant in eukaryotes.
Indeed, its name is somewhat of a misnomer since it is relatively
poorly induced by heat or other stresses above its very high basal
levels. In addition to the nucleocytoplasmic versions, there are related
isoforms in mitochondria, chloroplasts, and the endoplasmic reticu-
lum. Functionally, the cytosolic Hsp90 machine intersects with a
large number of cellular processes, and it has recently become a
drug target for the treatment of cancer and other diseases. All of
this has led to a massive explosion of the literature over the last
years. As of December 2011, a PubMed search with Hsp90 as the
keyword retrieves 6000 citations, and the combination “Hsp90 AND
cancer” almost 2000. The core of the Hsp90 community may not be
huge, but the fringes are enormous. This may not be a surprise for a
molecular machine that has been estimated to handle up to 10% of
all cellular proteins. In the jargon of the Hsp90 community, those
are the clients (the substrates).
Although Hsp90 has regularly been the subject of reviews, includ-
ing by several of the authors who contributed to this Special Issue, the
ﬁeld has become so vast that no single review can cover all aspects
anymore. A collection of reviews in one place comes much closer to
a comprehensive overview. This Special Issue is both for the diehard
Hsp90 aﬁcionados and for those looking for a serious jump-start. As
an updated snapshot of the ﬁeld, it nicely complements and expands
the efforts of your guest editor to make information about the Hsp90
chaperone machine available through his web site (http://www.
picard.ch). For the Hsp90 interactome, this includes the most recent
addition of the online database Hsp90Int.db at the same web address.
The Special Issue will also constitute a valuable companion for the bi-
annual conference series on “the Hsp90 molecular chaperone ma-
chine” (see http://www.hsp90.org) that has been going on for
almost ten years.
J. Johnson starts off with an overview of the Hsp90 family, its co-
chaperones and functions, embedded in an evolutionary perspective.
C. Prodromou discusses the intricate relationship between structure
and function for the highly dynamic molecular machine composed
of Hsp90 and co-chaperones. This review is complemented by that
of J. Buchner and coauthors who focus on the intricate and highly dy-
namic multistep Hsp90 chaperone cycle with its transitions driven by
ATP binding and hydrolysis and co-chaperone interactions. NMR
spectroscopy as a tool to study the structure and function of this com-
plex machinery in solution, as it works on clients as it were, takes
center stage in the chapter by S. Rüdiger and coauthors. M. Mollapour
and L. Neckers introduce the reader to yet another level of complexity
by reviewing how a bewildering number of post-translational0167-4889/$ – see front matter © 2012 Published by Elsevier B.V.
doi:10.1016/j.bbamcr.2012.02.004modiﬁcations control and ﬁne-tune this molecular machine. S. D.
Hartson and R. L. Matts compare the proteomic and genetic efforts
that have been made to deﬁne the Hsp90 interactome, and more gen-
erally the Hsp90-dependent proteome, and present the synthesis in a
highly useful form. F. J. Echtenkamp and B. C. Freeman reﬂect on the
role that co-chaperones play, beyond regulating the Hsp90 ATPase,
by expanding the “repertoire”, the “zone of inﬂuence” of Hsp90 et
al. One particular class of Hsp90 clients that are emerging are protein
complexes, as presented by T. Makhnevych and W. A. Houry. M. A.
Theodoraki and A. J. Caplan examine the connections between
Hsp90 and the ubiquitin system in quality control of cytosolic
proteins in physiological and pathological conditions. The next few
chapters then address the biological role of the Hsp90 machine for a
variety of organisms. For Y. Kadota and K. Shirasu, the biological
system is plants, where Hsp90 in collaboration with a speciﬁc set of
co-chaperones plays a particularly well-illustrated role in the
response against pathogens. J. Frydman and coauthors emphasize
the importance of Hsp90 as a host factor for viruses and explore the
diversity of requirements. U. Tatu and coauthors point out for
protozoan pathogens that their own Hsp90 is essential and thus a
potentially important drug target. K. Richter and coauthors then
take the reader on a tour of Hsp90 biology in mammalian metazoans,
except for the mouse that is covered, with a particular emphasis on
steroid physiology, in a chapter by E. R. Sanchez. Hsp90 even ventur-
ing outside of cells, its impact on wound healing and tumor cell inva-
sion are reviewed by W. Li and coauthors. Speaking of cancer, the
next two chapters thoroughly cover the current state of affairs.
G. Chiosis and coauthors present the ongoing efforts to bring Hsp90
inhibitors to the clinic for the treatment of cancer and possibly even
neurodegenerative diseases. L. Whitesell and N. U. Lin further discuss
this theme and an intellectual framework for developing effective
Hsp90-targeted chemotherapies. The two ﬁnal chapters give credit
to the fact that “Hsp90” is more than just “cytosolic Hsp90”. D. C.
Altieri and coauthors give an update on the mitochondrial isoform
of Hsp90, Trap1, and highlight its potential as a drug target in cancer.
Y. Argon and coauthors discuss Grp94, the isoform of the endoplasmic
reticulum that a more limited but no less important set of proteins
calls upon.
Despite everything that can be learned from this compendium, it
will also make brutally clear that so many more discoveries are need-
ed to answer key questions and harness all of this knowledge for
personalized medicine. As a way of teasing the reader to stay tuned
to the Hsp90 ﬁeld, let me mention a few of the open questions and
challenges. And note that most of them apply indiscriminately to all
of the Hsp90 isoforms and locales. We still do not really understand
how Hsp90 recognizes and binds its clients, nor how it does to
them whatever it does to them. Indeed, what Hsp90 does to clients,
606 Preface to Hsp90or even only one client, in structural and biochemical terms, has yet to be
worked out. Theremay be almost asmany answers to these questions as
there are clients, but there must at least be patterns. There are too many
known co-chaperones, and probably a fewmore unknown ones, to be all
present at the same time or even one after the other. How is this chore-
ography used, regulated and what for? Moreover, co-chaperones are
proteins in their own right, many of them moonlighting away from
Hsp90 as well. The study of Hsp90 at the organismic level, from bacteria
and viruses tomammals has considerably pickedup steam in the last few
years. Considering the numerous biochemical node functions of the
Hsp90 complex, there is undoubtedly a lot more exciting biology in
store. There is no question that in the Hsp90 ﬁeld, we are all believers,
believers in the therapeutic power of Hsp90 inhibitors to ﬁght viral, fun-
gal and protozoan infections, cancer, neurodegenerative and yet other
diseases. But we have yet to understand why cancer cells are more sen-
sitive to Hsp90 inhibitors, why inhibitors seem to work for some but not
for other cancers, what exact treatment regimen needs to be applied or
how Hsp90 inhibitors should be combined with other drugs. A lot of
food for thought and challenges, not bad for a protein that started out
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